• Protagenic received FDA pre-IND feedback backing a new US IND filing for PT00114 in generalized anxiety disorder.
• FDA flagged no clinical hold issues. No objections to the planned Phase 1 design or dose-escalation approach.
• IND submission targeted before end-2026. First patient dosing aimed for H1 2027, pending FDA clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-039410), on August 20, 2026, and is solely responsible for the information contained therein.